Vivos Therapeutics, Inc. announced compelling clinical data showing that treatment with its FDA-cleared Vida oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants. The company believes this finding underscores a major new commercial opportunity in the large and underserved global insomnia market.

Vivos focuses on the treatment of breathing-related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions. The Vida oral appliance is a central component of the company's medical device and healthcare service offerings.

The clinical trial results indicate a complete response rate among participants regarding the reduction of insomnia severity. This data highlights the potential efficacy of the Vida device in addressing sleep-related conditions beyond its primary applications.

Clinical Trial Outcomes

The study evaluated the impact of the Vida oral appliance on patients suffering from insomnia. The results demonstrated a consistent positive response across the entire participant pool.

The company positions these results as a validation for expanding the commercial application of its Vida device. Vivos aims to leverage this data to capture a share of the global insomnia market.

Vivos Therapeutics, Inc. has extended its strategic financing agreement with Streeterville Capital, LLC through August 31, 2026, to allow more time for capital-raising activities. The extension reaffirms Streeterville's commitment to convert up to $4.5 million of outstanding debt into a combination of perpetual, non-convertible preferred stock and common stock. The company determined that the original agreement's timeframe was insufficient to complete its capital requirements. The additional time is intended to allow the company to raise needed equity in an organized fashion and to permit a previously announced rights offering to commence during that period.

Financing Agreement Details

The extended agreement maintains the core terms of the original strategic financing deal. Streeterville Capital will convert the specified debt amount into equity, providing Vivos with financial flexibility. The conversion involves both preferred and common stock, aligning with the company's long-term capital structure strategy. The conversion occurs once the company raises $2.6 million and will continue up to a maximum of $4.5 million. This structure supports the company’s plan to strengthen its stockholders’ equity and maintain compliance with the continued listing standards of The Nasdaq Stock Market.

Key Terms of the Extension

The extension ensures Vivos can proceed with its capital-raising initiatives without the immediate pressure of the previous deadline. The company focuses on treating breathing-related sleep disorders, including mild-to-severe obstructive sleep apnea.